Stromal expression of some matrix metalloproteinases (MMPs) has been associated with increasing tumour burden in prostate cancer. We investigated the expression of mRNA (by RT-PCR) and protein (by zymography and western blotting) of MMPs and endogenous inhibitors (tissue inhibitors of metalloproteinases, TIMPs) in two parent epithelial prostate cancer cell lines and sublines of increasing invasive/metastatic potential. Expression of membrane type MMPs, MT1-MMP and MT3-MMP mRNA was higher in PC3-derived than in LNCaPderived lines, whereas MT2-MMP mRNA expression was higher in the LNCaPderived than in PC3-derived cell lines. Active MT1, MT2 and MT3-MMP protein levels were similar in all lines, but processed MT-MMPs, indicative of latent MMP activation, were increased in more aggressive sublines. Expression of MMP-1, MMP-13 and TIMP-1 was higher in the more aggressive sublines and may be implicated in invasive/metastatic ability. Regulation of MMP-1 and MMP-13 expression may offer important therapeutic options for treating patients with prostate cancer.
Introduction
Prostate cancer is the most common male cancer and second highest cause of cancer mortality in men in Western society. It is a heterogeneous disease, which may be indolent and therefore not require intervention, may remain localized to the prostate gland but be clinically significant ( > 95% 5 y survival), or may be invasive and metastatic, primarily to lymph nodes and bone (5% 5 y survival). 1, 2 Despite extensive studies of prostate cancer progression, it is still not understood why some cancers remain localized to the prostate, whilst others are highly invasive and metastatic. Such an understanding would facilitate advances in diagnostic and therapeutic outcomes.
A key step in the complex process of cancer progression and the establishment of bony metastases is the degradation of the extracellular matrices. This is achieved by a range of proteases including the matrix metalloproteinases (MMPs). MMPs form an increasingly diverse family of zinc-dependent endopeptidases 3 that can degrade the basement membrane and extracellular matrix (ECM) during physiological tissue remodelling, as well as in pathological conditions such as tumour invasion and metastasis. Most MMPs are secreted as inactive pro-enzymes; their proteolytic activity is regu-lated by zymogen activation by extracellular proteases or other MMPs or by inhibition of specific inhibitors, tissue inhibitors of metalloproteinases (TIMPs) or other nonspecific protease inhibitors. 4 -6 This implies that the balance between MMP and TIMP levels is a critical determinant of the net proteolytic activity at any given time. MMPs are classified on the basis of their substrate specificity and include collagenases (e.g. MMP-1, -8 and -13), gelatinases (eg MMP-2, -9), stromelysins (eg MMP-3, -7, -10, -12), membrane-type MMPs (MT-MMPs, eg MTMMPs -1 to -5, also known as MMP-14, -15, -16, -17, -24, respectively) and other MMPs (eg MMP-19, -20, -23, -26 and -28). 7 -9 The MT-MMPs contain a transmembrane domain anchoring the enzyme to the cell surface. 10 Of five MT-MMPs (MT1 -MT5-MMP) identified so far, 11 -15 MT1-MMP is the most characterized and, in association with TIMP-2, is involved in the activation of pro-MMP-2 16, 17 and pro-MMP-13. 18 MT2-and MT3-MMP can also activate pro-MMP-2 but with lower efficiency. MT-MMPs are synthesised in a latent pro-form (MT1-MMP 63 kDa, MT2-MMP 68 kDa, MT3-MMP 64 kDa) that contains a putative furin or proprotein convertase motif (RXKR). Cleavage at this site produces an active MT-MMP (MT1-MMP 60 kDa, MT2-MMP 62 kDa, MT3-MMP 60 kDa), which is further processed to a 45 -50 kDa form once activation of pro-MMP2 has been achieved. 19, 20 As well as being responsible for activating latent MMPs, MT-MMPs also exhibit proteolytic activity against components of the ECM, potentially facilitating egress of cancer cells from a tumour deposit. MMP activities are regulated by specific inhibitors, TIMPs, four of which (TIMP-1 -4) have been identified thus far, 22, 23 In prostate cancer patients, analysis of MMP mRNA and protein levels in patient serum and tissue samples has shown that increased expression of MMP-1, 24, 25 MMP-2, 26 -32 24, 29 MMP-7 and MMP-9 27,34 is correlated with advanced or metastatic disease. More MT1-MMP is expressed in high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer compared with benign prostate tissue. 35 However, MMP expression during cancer progression is often the result of the stromal microenvironment stimulating MMP production in tumour cells, or stromal cells themselves producing MMPs as they surround an invasive tumour front. 36 -38 It is therefore difficult to ascertain from the literature whether increased MMP production is a function of invasive prostate cancer cells per se and whether this could potentially be used as a marker to differentiate between non-invasive and invasive prostate cancer.
This study aimed to investigate the production of MMPs and TIMPs, in the absence of stroma or ECM, by prostate cancer epithelial cells and their sublines that have been developed for their ability to metastasize in nude mice. Two parent lines were used. LNCaP 39 is androgensensitive and non-invasive when implanted subcutaneously (s.c.) in nude mice; an androgen-independent (AI) cell line, LNCaP-C4, obtained from a tumour-bearing mouse 4 weeks after castration, produces a soluble, nonandrogenic factor that stimulates PSA production in an autocrine fashion. Further characterization of LNCaP-C4 produced a subline, LNCaP-C4-2, that metastasizes to lymph node and bone after s.c. or orthotopic implantation. [40] [41] [42] [43] [44] is AI; PC3-M was derived from a liver metastasis following injection of PC3 cells into the spleen of nude mice, and PC3-MM2 was grown from a bone metastasis after injection of PC3-M cells. 46, 47 Using reverse-transcriptase polymerase chain reaction (RT-PCR) and western blotting, we detected differential expression of mRNA and protein for a range of MMPs and TIMPs in these prostate cancer cells. Of particular interest, we report for the first time the expression of MMP-13 by prostate cancer epithelial cells and show that MMP-13, MMP-1 and TIMP-1 expression is relatively increased in the PC3 sublines compared with the LNCaP-derived lines. MMP-1 and MMP-13 are collagenases that preferentially degrade type I and type II collagen, respectively. We propose that the overexpression of MMP-1 and MMP-13 in invasive prostate cancer cells may contribute to their ability to metastasize, and could therefore potentially be used as markers of aggressive prostate cancers.
Materials and methods

Cell culture
The human prostate cancer cell line, LNCaP, was from Dr L Chung (University of Virginia, VA, USA) and LNCaP sublines, LNCaP-C4 and LNCaP-C4-2 cells, from UroCor, USA. PC3 cells were from the American Type Culture Collection (ATCC, Rockville, MD, USA) and PC3 sublines, PC3-M and PC3-MM2, from Dr C Pettaway, MD Anderson Cancer Centre (TX, USA). LNCaP, LNCaP-C4 and LNCaP-C4-2 cells were grown in complete T medium (80% v/v Dulbecco's Modified Eagle Media, 20% v/v F12 nutrient mixture (both from Gibco BRL Life Technologies, Melbourne, VIC, Australia), supplemented with 5% fetal calf serum (Trace Biosciences, Sydney, NSW, Australia), insulin (5 mg/ml; Novo Nordisk, Denmark), triiodothyronine (13.65 pg/ml), apo-transferrin (5 mg/ml), biotin (0.244 mg/ml), adenine (25 mg/ml; all from Sigma Chemical Co., St Louis, MO, USA), penicillin (50 U/ml) and streptomycin (0.05 mg/ml; Gibco BRL Life Technologies). PC3, PC3-M and PC3-MM2 cell lines were maintained in RPMI 1640 media (Gibco BRL Life Technologies), supplemented with 10% fetal bovine serum (Trace Biosciences), penicillin (50 U/ml), streptomycin (0.05 mg/ml) and 0.2 mM L-Glutamine (Gibco BRL Life Technologies). All cells were maintained at 37 C in 5% CO 2 and passaged with trypsin/EDTA (Gibco BRL Life Technologies) when confluent.
In vitro invasion assay
The ability of the cell lines to invade a Matrigel 2 (Integrated Sciences P/L, Willoughby, NSW, Australia) coating in a transwell chamber assay was assessed using serum-free, antibiotic-free medium in triplicate by the method of Repesh. 48 Cells were applied at 5000 cells/ 200 ml (700 ml was added to the outer well to prevent dehydration), incubated at 37 C, 5% CO 2 for three doubling times before removing medium from the transwell and outer well, rinsed with PBS and stained with 0.5% crystal violet in 50% methanol/water for 10 min at room temperature. Excess dye was washed away with tap water. Cells were examined by microscopy.
RNA preparation and cDNA synthesis
When 80% confluent, cells were harvested with 0.2% trypsin/EDTA and pelleted by centrifugation at 1500 rpm for 5 min. Total RNA was extracted by lysing the cell pellet in 1 ml Tri Reagent (Sigma Chemical Co., St Louis, MO, USA) as per the manufacturer's instructions. RNA (2 mg) was used to prepare cDNA in a reaction containing 1 ml of 100 mM random hexamer primers (Amersham Pharmacia Biotech, Castle Hill, NSW, Australia), 6 ml of 56 Moloney Murine Leukemia Virus (M-MuLV) reaction buffer (Progen Industries, Richlands, QLD, Australia) and 1.5 ml of 10 mM dNTP (Perkin Elmer, Boston, MA, USA). RNase-free water was added to a total volume of 27.4 ml. The mixture was incubated at 72 C for 3 min and then chilled on ice. RNase inhibitor (0.6 ml 1 U/ ml of M-MuLV reverse transcriptase (13.3 U/ml; Progen Industries, Richlands, QLD, Australia) were added and the sample incubated at 37 C for 2 h. The reaction was terminated by incubation at 75 C for 10 min and the cDNA preparation stored at 7 80 C.
Polymerase chain reaction
Polymerase chain reaction (PCR) amplification of MMP, MT-MMP and TIMP cDNA was performed in a reaction containing 5 ml of 106 type IV polymerase buffer, 1.5 mM MgCl 2 , 0.2 mM dNTPs, 20 pmol MMP 5 0 primer and 20 pmol MMP 3 0 primer, 0.5 ml Taq polymerase, 1 ml cDNA template and sterile RNase free water to a total volume of 50 ml. All PCR reagents were from Advanced Biotechnologies (Surrey, UK) and all primers were synthesized by Gibco BRL Life Technologies. Primer sequences were from published data for MMP and TIMP amplification and are listed in Table 1 . 49, 50 LNCaP and PC3 cDNAs were used to optimize the conditions for RT-PCR for each primer set by comparing different concentrations of magnesium chloride and different cycle numbers. The concentration that gave the strongest signal on a 2% agarose gel stained with ethidium bromide was chosen as the optimal concentration for that primer set. The optimal Mg 2þ concentrations were: MMP-1, 3, -10, TIMP-1 and -2, 2 mM; MMP-13 and MT-MMP-1, -2 and -3, 2.5 mM. The primer sets used yielded one band of the predicted size, and all PCR products were found to be in the linear range after 35 cycles of amplification. cDNA was amplified using a HYBAID PCR machine at 94 C for 4 min (1 cycle), followed by 35 cycles of 94 C for 30 s, annealing temperature for 30 s and 72 C for 1 min, and a final step of 72 C for 10 min. 49 Amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was undertaken to monitor the quality of the RNA extraction and cDNA synthesis and to ensure that equivalent amounts of cDNA were used in MMP/ TIMP amplifications. The PCR mixture for GAPDH consisted of 5 ml of 106 polymerase buffer, 0.75 mM MgCl 2 , 0.5 mM dNTPs, 10 pmol GAPDH 5 0 primer (5 0 -CCA CCC ATG GCA AAT TCC ATG GCA-3 0 ), 10 pmol 3 0 primer (5 0 -TCT AGA CGG CAG GTC AGG TCC ACC-3 0 ), 0.5 ml Taq polymerase, 2 ml cDNA template and sterile RNase-free water to give a volume of 50 ml. The PCR conditions were 94 C for 4 min (1cycle), followed by 94 C for 30 s, 60 C for 30 s and 72 C for 90 s (24 cycles), and a final step of 72 C for 10 min. PCR products were separated on a 2% agarose gel stained with ethidium bromide or silver staining of a 4% acrylamide gel and quantified using a Kodak Digital 
Scientific Imaging System (Kodak, Rochester, NY, USA). Expression of MMPs relative to GADPH was estimated by densitometry.
Preparation of conditioned media
When cells were approximately 80% confluent, medium was removed and cells were rinsed (36) with PBS and then incubated in serum-free medium for 24 h. The serum-free medium was removed, centrifuged at low speed to remove cellular debris and the supernatant then concentrated using a Jumbosep 2 (Pall Gelman Sciences, Ann Arbor, MI, USA) 10 kDa molecular weight cut-off diafiltration unit. If further concentration was required, this was achieved using a Centriprep 3 or Centricon 3 concentrator (Amicon, Beverly, MA, USA). The protein concentration of the secreted protein fraction was determined using a BCA protein assay kit as per the manufacturer's instructions (Pierce, Rockford, IL, USA).
Preparation of cell lysates
Cells at 80% confluence were harvested with 0.2% trypsin/EDTA, pelleted by centrifugation at 1500 rpm for 5 min and resuspended in 500 ml of M-Per (Mammalian Protein Extraction Reagent, Pierce, Rockford, IL, USA containing EDTA-free protease inhibitor cocktail (Roche Molecular Biochemicals). The protein concentration of the supernatant was determined using a BCA protein assay kit as per the manufacturer's instructions (Pierce, Rockford, IL, USA).
Gelatine zymography
Zymography (substrate gel electrophoresis) was used to detect MMP activities that were secreted into conditioned media. The method, modified from Lyons et al, 51 involved copolymerizing 0.1% gelatine into standard Laemmli SDS gels and resolving the samples under non-reducing conditions. Gelatine was incorporated into a separating gel (7.5%) cast in a slab with a stacking gel (4%). Samples were incubated in 56 non-reducing sample buffer (0.25 M Tris -HCL, pH 6.8, 10% SDS, 50% v/v glycerol and 0.5% bromophenol blue) for 30 min on ice to achieve full denaturation. Duplicate gelatine gels (A and B) were electrophoresed at 100 V. Gel A was washed for 30 min each in l00 ml of buffer 1 (50 mM Tris, 2.5% Triton X-100, pH 7.5) and buffer 2 (50 mM Tris, 5 mM CaCl 2 , 1 mM ZnCl 2 , 2.5% Triton X-100, pH 7.5), followed by incubation in buffer 3 (50 mM Tris, 5 mM CaCl 2 , 1 mM ZnCl 2 , pH 7.5) for at least 12 h at 37 C with gentle shaking. Gel B was incubated under 0mM Tris, 5mM CaC12, 1 mM ZnC12, 2.5% similar conditions except that buffers 1 -3 contained 10 mM EDTA. All chemicals were from Sigma Chemical Co. (MO, USA). After incubation in buffer to develop the enzymatic activity, the gels were fixed in 50% methanol/ 7% acetic acid, then stained in 0.002% Coomassie blue G250 for several hours. No destaining was necessary. Standard proteins were incorporated into the zymograms so that molecular weights could be assessed.
Western blotting
Equal amounts of protein from cell lysates and conditioned media were separated under non-reducing conditions on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. Membranes were blocked for 12 h at 4 C in blocking buffer (5% skim milk powder in PBS/0.1% Tween 20), washed 36 with PBS/0.1% Tween 20 and incubated in mouse IgG anti-human MMP or TIMP-1 or -2 antibodies (0.1 mg/ml; Calbiochem-Novabiochem Pty, San Diego, CA, USA) in blocking buffer for 4 h at room temperature before washing 36 with PBS/ 0.1% Tween 20. Membranes were then incubated in goat anti-mouse IgG conjugated to horseradish peroxidase (1 : 1000; BioRad, Hercules, CA, USA) for 2 h at room temperature, washed 36 with PBS/0.1% Tween 20 and the blot developed using an enzyme-chemiluminescence (ECL) kit (Amersham Pharmacia Biotech, Castlehill, NSW, Australia) as per the manufacturer's instructions. The bands were quantified by densitometric analysis (Kodak Digital Scientific Imaging System).
Results
In vitro invasion assays
To confirm the increasing invasiveness of the sublines derived from parent prostate cancer cell lines, an in vitro invasion assay was performed. Results from the PC3-derived lines (Figure 1 ) indicate that more PC3-MM2 cells invaded Matrigel 2 than PC3-M cells that in turn were more invasive than PC3 cells. The LNCaP-derived lines did not differ in their invasive capacity by the assay (data not shown).
MMP and TIMP expression in prostate cancer cell lines mRNA expression of MMPs. MMP mRNA expression was determined by RT-PCR using published primers. 49 As cell density can affect the levels of mRNA expression of some MMPs in vitro, 52 -55 we determined the optimal harvest time using PC3 cells as a representative cell line and examined expression of representative MMPs: MMP-1, MT1 and MT2-MMP by RT-PCR. PC3 cells at various cell densities were obtained by seeding increasing numbers of cells and harvesting at the same time (designated Gl -G8), or by seeding at the same density and harvesting at 24 h intervals up to 6 days (designated D1 -D6). Expression of MMP-1 and MT1-MMP increased as the cell density increased from G1 to G8, whilst that of MT2-MMP remained the same (Figure 2) . MMP-1, MT1-and MT-MMP expression all increased from Dl to D3, and thereafter remained constant ( Figure 2 ). As these results indicated that MMP expression was constant after 72 h, around the same time for the cells to reach 70% confluence, other RT-PCRs were performed on cells harvested after 72 h.
Relative mRNA expression by LNCaP-and PC3-derived lines of MMP-1, -3, -7, -10 and -13, of MT1-MMP, MT2-MMP and MT3-MMP and of the specific regulators, TIMP-1 and TIMP-2 is shown in Figure 3 . Expression of MMP-7 was undetectable and that of MMP-10, weak, and we did not detect message for MMP-2, MMP-8, MMP-9, MMP-11 or MMP-12 in any prostate cancer cell line tested (data not shown). As the mRNA levels of some MMPs varied in different LNCaP-or PC3-derived cells, a semi-quantitative RT-PCR test was conducted, in which PCR products were assessed after different numbers of PCR cycles (Table 2) . MMP-1 mRNA expression was low in the LNCaP-derived cell lines and the PCR product from 35 cycles could only be detected on gels stained with silver (not shown) but not with ethidium bromide even after 45 PCR cycles. After silver staining, MMP-1 mRNA levels appeared higher in LNCaP-C4 and LNCaP-C4-2 cells than in LNCaP cells. In contrast, MMP-1 mRNA expression was readily detected in all PC3-derived cell lines (Figure 3) . Ratios of MMP-13 mRNA compared with GADPH mRNA were higher in LNCaP-C4-2 cells than in LNCaP or LNCaP-C4, and lower in PC3-M than in either PC3 or PC3-MM2 cells.
MT1-MMP mRNA was detectable in the PC3-derived cell lines on ethidium bromide-stained gels (Figure 3 ), but only in silver-stained gels of the LNCaP series of lines (data not shown). More MT2-MMP mRNA expression was seen in LNCaP-C4 than in LNCaP or LNCaP-C4-2 cells, whilst MT2-MMP mRNA expression was higher in PC3 than in PC3-M or PC3-MM2 cells. Expression of mRNA for MT3-MMP was relatively higher in LNCaP-C4-2 than LNCaP-C4 or LNCaP cells, and was also higher in PC3-MM2 than in PC3-M or PC3 cells.
After 35 cycles, TIMP-1 mRNA expression was detectable in LNCaP-C4-2 cells but not in LNCaP or LNCaP-C4 cells ( Figure 3) ; it was equivalent in PC3-derived cell lines (Figure 3 ). TIMP-2 mRNA expression was similar in all cell lines (Figure 3) .
Gelatine zymography. To study protein expression, initially a comparison of gelatine zymography on secreted proteins concentrated from serum-free conditioned media of the cell lines was performed. The zymograms were incubated in activity-developing buffer for various times to assess the kinetics of gelatinase activity. Only the 48 h time point is shown in Figure 4 . LNCaP-derived cells secreted bands at 5 kDa, several between 68 and 80 kDa and at 175 kDa and above. Each of the three PC3 sublines exhibited gelatinolytic activities with MWs 80, 63 and 43 kDa, respectively, but the levels of activity differed in the three cell lines.
The 80 kDa activity was strongest in PC3-M cells, and was detectable in conditioned media from both PC3 and PC3-M cells after 12 h incubation, but only after 24 h in medium from PC3-MM2 cells. The 63 and 43 kDa activities were stronger in both PC3-M and PC3-MM2 cells than in PC3-conditioned medium. No bands were present in parallel gels incubated with the collagenase inhibitor, EDTA (data not shown), confirming that the enzymes were collagenases.
Western analysis of MMP proteins
Expression of MMP proteins was confirmed by western blotting using commercially available antibodies; MMP-8 and -10 proteins were not tested. MMP-1 protein was found in cell lysates of the PC3 sublines ( Figure 5A ; MW 57/52 kDa), whilst secreted forms were found at 75 and 43 kDa. These may correlate with the bands seen at 80, 60 and 43 kDa on zymography (Figure 4 ). MMP-1 protein (60 kDa) was also readily detectable in cell lysates from LNCaP, LNCaP-C4 and LNCaP-C4-2, despite the fact that MMP-1 mRNA could only be detected from these lines on silver-stained gels (data not shown). The latent form of MMP-1 was secreted by the LNCaP cells and its sublines ( Figure 5B) ; the active form was also secreted by LNCaP-C4-2 cells and by each of the PC3-derived cell lines ( Figure 5B ). MMP-7 (MW 28 kDa) was secreted by the PC3 sublines. MMP-9 protein was not detected using antibodies from Calbiochem nor by two other antibodies provided by colleagues (results not shown). Western blotting of total cell lysates for MMP-13 expression revealed multiple nonspecific bands (data not shown); however, western blot analysis of conditioned media showed that levels of MMP-13 protein (60 and 48 kDa) secreted into the media were, in decreasing order, PC3-MM2 > PC3-M > PC3 cells, and MMP-13 protein was also higher in conditioned medium from LNCaP-C4-2 cells than from LNCaP-C4 or LNCaP cells ( Figure 5B ). To our knowledge, this is the first report of MMP-13 protein expression in prostate cancer cell lines. MMP-2, -11 and -12 were not detected in either the LNCaP-or PC-3 derived cell lines (data not shown).
Equal concentrations of cell lysates were electrophoresed under non-reducing conditions and tested for MT1-, MT2-and MT3-MMP expression by western blotting. Using MT1-MMP antibody, we detected a band at 63 kDa, which may correspond to the pro-form of MT1-MMP, a second band at 60 kDa correlating with active MT1-MMP and a third band at 45 kDa, corresponding to the processed form of MT1-MMP ( Figure  5A ). Expression of active MT1-MMP appeared higher in LNCaP-C4 cells than in LNCaP or LNCaP-C4-2, and was increased in PC3 cells compared with PC3-M or PC3-MM2 cells. The pro-and processed forms of MT1-MMP were predominantly found in the PC3 sublines and levels did not vary significantly in the more invasive cell lines. Expression of active MT2-MMP was variable within the LNCaP and PC3 cell lines, and not related to invasive potential of the cells ( Figure 5A ). However, more active MT2-MMP and MT3-MMP were present in cell lysates of the LNCaP sublines than in those derived from PC3 ( Figure 5A ). Levels of processed MT3-MMP were higher in PC3-MM2 cells than in PC3-M or PC3 cells.
TIMP-1 protein levels were equivalent in the total cell lysates of all cell lines tested ( Figure 5A ). LNCaP-C4-2 cells secreted more TIMP-1 protein than LNCaP or -10  2  1  0  2  1  1  MMP-13  3  3  3  1  1  1  MT1-MMP  0  0  0  3  1  2  MT2-MMP  3  3  3  2  1  1  MT3-MMP  3  2  3  3  1  2   a In these cases, more sensitive silver staining of gels showed the presence of mRNA after 35 cycles. Silver-stained gels were not performed in all cases. b No band was detected after 35 cyles and 40 cycles were not used in these cases. 4 indicates that PCR products were detectable on ethidium bromide stained gels after 25 cycles, 3 after 30 cycles, 2 after 35 cycles, 1 after 40 cycles, or 0, not detectable after 40 cycles. LNCaP-C4 cells, whilst secreted TIMP-l protein levels were equally high in each PC3-derived cell line ( Figure  5B ). Similar levels of TIMP-2 protein expression were present in lysates of LNCaP-and PC3-derived cell lines ( Figure 5A) , with little being secreted by any cells ( Figure  5B ).
Discussion
The process of tumour invasion and metastases is complex. It involves the escape of tumour cells from their primary site into the surrounding stroma, intravasation into the vasculature or lymphatic system, adhesion at a distant site, extravasation and finally establishment and growth at a secondary site. In prostate cancer, a major site of metastasis is bone. Experimental studies suggest that interactions between prostate cancer cells and bone cells can promote osteolysis, resulting in space and the release of growth factors essential for osteoblastic growth. 2 However, why prostate cancer cells preferentially target bone is not yet fully understood. 2,56 -58 The role of MMPs and their inhibitors in cancer progression has been extensively studied. 7, 22, 59 In prostate cancer tissues, increasing expression of MMPs-1, 24,25 -2, 26 -32 -3, 24,29 -7 33 and -9 27, 34 has been associated with increasing cancer burden. However, these studies did not distinguish between expression by stromal or epithelial cells that may interact to cause cancer progression. Stromal cells can themselves produce MMPs and/or factors that induce MMP production by a range of tumour cells including breast, colon and melanoma. 60 -64 The aim of the current study was to determine whether MMPs were inherently produced by prostate cancer cells in the absence of stromal or ECM influences and whether there were any differences in MMP expression in cells derived from lines of increasing invasive/metastatic potential. The LNCaP-C4 and LNCaP-C4-2 have been shown in in vivo studies to be more aggressive and to have more metastatic ability than the LNCaP cells. 40 -44 Similarly, PC3 M and PC3 MM2 have been described as more aggressive in vivo than PC3 cells. 46, 47 We wished to confirm the invasive abilities of these prostate cancer cell lines in vitro. In our hands, the LNCaP derived lines shared similar invasive capacities, others have also reported their ability to invade Matrigel 2 . 80 However, PC3-MM2 cells, derived from a bony metastasis, were more invasive than PC3-M or PC3 cells, based on the ability of the cells to degrade and invade Matrigel 2 ( Figure 1 ). Matrigel 2 , extracted from mouse sarcoma, is composed of growth factors and several ECMs including laminin, collagen type IV and heparan sulphate proteoglycans. 65 Their degradation is necessary to facilitate mobility through Matrigel 2 and therefore measures the ability of the cells to degrade and invade through ECMs containing similar molecules in vivo.
Since MMPs and their inhibitors are reportedly involved in tumour progression and metastasis, we next examined the gene and protein expression pattern for MMPs, TIMPs and MT-MMPs in the six prostate cancer cell lines. We failed to detect any MMP-2, -3 or -9 at either the mRNA or protein level and we detected only negligible amounts of MMP-7 protein but not mRNA. It is possible that the temporal relationship between mRNA and protein expression could account for this discrepancy. It is likely that the association of overexpression of MMP-2, -3 and -9 with increasing cancer burden in patients is linked to the presence of stroma. Our aim was to determine whether prostate epithelial cells produced MMP's in the absence of stroma or ECM. A recent study has shown that the presence of stromal cells in co-culture with human prostate cancer cell lines resulted in enhanced levels of pro-MMP-9 (produced by prostate cells) and down-regulation of TIMP expression by stromal cells. 66 Moreover, MMP-9 mRNA expression or secretion were not detected in 1-LN human tumour cells, a metastatic cell line derived from PC3 cells, 67 unless the e glycoform of plasminogen (Pg e) that binds to plasminogen receptor type 2 (Pg2) was also available at the cell surface. 68 Only Pg e, and not other glycoforms of Pg, could stimulate MMP-9 expression and activation; no active MMP-9 was detected in the absence of Pg e. 68 Our study has demonstrated that MMP-1, MMP-13, MT1-, MT2-and MT3-MMP and TIMP-1 and -2 are expressed by prostate cancer cells themselves in the cell lines tested in the absence of stroma. Our finding that MMP-1 and -13 expression and secretion are increased in the sublines when compared with the parental lines suggests that these collagenases are involved in the increased invasive capacity of the sublines. The relative levels of MMP-1 and MMP-13 protein expression did not correlate with the mRNA levels, suggesting that posttranslational regulation and/or modifications could be important. Low levels of MMP-13 mRNA have been reported in PC3 but not in LNCaP cells. 49 In contrast, we detected MMP-13 mRNA (Table 2 ) and protein in both LNCaP and PC3 cells and their sublines. To our knowledge our study is the first report of MMP-13 protein expression in prostate cancer cells. MMP-13 was initially isolated from breast tissues, 69 where it was overexpressed in cancers compared with benign lesions or normal mammary gland, but its production was identified as stromal. 70 Our data indicate that prostate cancer epithelial cells can express MMP-13 mRNA and secrete MMP-13 protein in the absence of stromal cells. Expression of collagenases, including MMP-1 and -13 by prostate cancer cells in isolation from stroma suggests a mechanism whereby cells can extravasate from the circulation.
Low levels of MT1-MMP mRNA expression were only detectable in the LNCaP-derived lines using silverstained gels (data not shown) consistent with the findings of a recent study that detected MT1 -MMP in androgenindependent, but not in LNCaP, prostate cancer cell lines. 71 At the protein level, MT1-MMP was found in each LNCaP-derived line ( Figure 5A ), and confirmed by flow cytometric analysis of surface fluorescence (data not shown). Western blots revealed that low levels of active, pro-and processed forms of MT1-MMP were present ( Figure 5A ). By contrast, MT2-MMP and MT3-MMP mRNAs ( Figure 3 ) and active MT2-MMP and MT3-MMP protein were strongly expressed in the LNCaP lines ( Figure 5A ) with increased processed MT2-MMP and MT3-MMP in the more aggressive LNCaP-C4-2 compared with LNCaP cells. Expression of MT-MMP mRNAs was similar in each PC3-derived line, whereas, compared with the parental PC3 line, MT2-MMP mRNA decreased and MT3-MMP mRNA increased in the PC3 sublines ( Figure 3) . We detected pro-and active forms of MT1-, MT2-and MT3-MMP proteins in all of the PC3-derived lines ( Figure 5A ). Processed MT2-and MT3-MMP were increased in the PC3-MM2 line compared with the other lines, regardless of the mRNA and/or active or proprotein expression, suggesting that, although transcriptional and translational regulation may occur, invasive cells tend to process their MT-MMPs more readily than less invasive cells. Processed MT-MMPs are thought to result from active MT-MMPs activating pro-MMPs. 19 The increase in processed MT2-and MT3-MMPs in the PC3-MM2 line suggests that activation of target latent MMPs has been carried out, possibly due to increased levels of latent MMP in more invasive cells or to post-translational regulation of MT-MMPs. The levels of processed MT-MMP may thus provide a measure of activated functional MT-MMP.
TIMP-1 mRNA was relatively higher in LNCaP-C4-2 cells than in the other LNCaP lines (Figure 3 ) correlating with the levels of secreted TIMP-l protein ( Figure 5B ), but little TIMP-l protein was detectable in their cell lysates ( Figure 5A ). Strong TIMP-1 mRNA ( Figure 3 ) and protein expression in cell lysates at approximately equivalent levels ( Figure 5A ) were seen in the PC3-derived lines, and similar levels of TIMP-1 were secreted by PC3-MM2, PC-3M and PC3 cells ( Figure 5B ). Moreover, both active and latent TIMP-1 were secreted by LNCaP-C4-2 and by each of the PC3-derived lines ( Figure 5B ). TIMP-2 mRNA ( Figure 3 ) and protein ( Figure 5 ) levels were negligible in LNCaP-derived and PC-3-derived cell lines. Hence, either TIMP-2 may not play a role in the biology of tumour invasion by these prostate cancer cells, or may require a stromal component for its expression and regulation. Indeed, TIMP-1 was down-regulated in stromal cells when human prostate cancer cells and stromal cells were co-cultured. 66 Whilst it is possible that high levels of MMPs and TIMP-1 in PC3-M and PC3-MM2 cells sublines may reflect an increase in their proliferative ability compared with PC3 cells or an increased turnover of biologically available MMPs, since high rates of MMP expression and activation could be balanced by high rates of inhibition by TIMP-1, it is also likely that the balance between MMP and TIMP-1 expression lies in favour of MMP in these cell lines. Our experiments do not discriminate between these possibilities.
In normal adult bone remodelling, osteoblasts produce and secrete high levels of inactive and latent TGFb that is sequestered onto the ECM and activated upon bone resorption by osteoclasts. 72 Prostate cancer cells express and secrete urokinase type plasminogen activator (uPA), 73 with increased expression in more invasive prostate cancers. 74 Recent reports have shown that osteoblastsecreted latent TGFb induces the secretion by prostate cells of uPA, which in turn activates TGFb. 75 Active TGFb up-regulates expression of MMP-9, MMP-2, MMP-1 and MMP-7, 76 leading to increased aggression by the prostate cancer cells. In preliminary studies, we found that TGFb had differential effects on MMP-1 and MMP-13 production in LNCaP and PC-3 parent cell lines (data not shown). Unlike PC3 cells, LNCaP cells exhibit a less osteolytic phenotype in vivo and have not been shown to degrade collagen matrices in vitro. 77 Differences in their response to TGFb may reflect their slower growing and less invasive nature compared with PC3 cells or a variability in sensitivity to TGFb, perhaps due to differential expression of TGFb receptors and/or Smads, which are responsible for the intracellular transduction of TGFb signals. 78 In human dermal fibroblasts, cytokine-induced MMP-1 gene expression is abrogated by TGFb, but also by Smad3 or 4 79 and TGFb failed to repress MMP-l promoter activity in Smad3-deficient murine embryonic fibroblasts. 79 It would be of interest to perform further studies of the effects of TGFb on MMP expression in the LNCaPand PC3-derived cell lines and to determine whether there is a difference in the expression of Smad3 which could affect the TGFb signalling pathway in these cells.
Conclusions
In the absence of stroma or ECMs, we have shown that, compared with the parent lines, LNCaP and PC3, the more invasive prostate cancer cell lines, LNCaP-C4-2 and PC3-MM2, produce higher levels of MMP-1 as well as MMP-13, and more processed MT1-, MT2-and MT3-MMPs. This is despite the fact that more TIMP-1, which can inhibit activated MMP-1, was also secreted by LNCaP-C4-2 than by their counterpart LNCaP and LNCaP-C4 cells, suggesting that the balance between active MMP-1 and TIMP-1 lay in favour of the MMP-1 in this cell line. MMP-1 and MMP-13 degrade type I and type II collagen, major components of bone and basement membrane, respectively. Degradation of the basement membrane would facilitate extravasation from the primary site and escape into the circulation or extravasation from the circulation and into a distant secondary metastatic site, such as bone. Increased osteolysis (degradation of type I collagen) is a necessary first step in the establishment of bony metastases and is thought to stimulate the release of activated growth factors, including TGFb, that are mitogenic for cancer cells and bone cells. Processed MT-MMPs are thought to provide a measure of functional MT-MMP that can degrade the ECM.
We speculate that expression of both MMP-1 and MMP-13, as well as increased processing of MT-MMPs by prostate cancer cells in the absence of stroma as shown here, may be important in invasion and could be relevant in targeting prostate cancer cells to bone. Understanding why certain prostate cancers progress to bone has serious implications for patient care and treatment. Further work to investigate the expression of MMP-1 and MMP-13 as markers for metastatic prostate cancer and as potential therapeutic targets warrants further investigation and is in progress.
